Case Study: Synthetic sgRNAs Enable Researchers to Study Viral Infection in Resting Human CD4+ T Cells
In a new case study, Synthego and Lonza discuss their recent collaboration with Dr. Manuel Albanese and exciting results in gene editing of resting human CD4+ T cells. This case study highlights how to achieve efficient gene editing in CD4+ T cells, overcoming the traditional challenges related to cell viability and maintaining resting state. The corresponding protocol provides a step-by-step guideline along with a tips and tricks section for performing gene editing using Synthego’s sgRNA in combination with Lonza's 4D-Nucleofector® System.
By implementing an optimized workflow that includes interleukin supplementation, sgRNA, and the 4D-Nucleofector® System, Dr. Manuel Albanese and his colleagues achieved knock out rates greater than 98% of up to six genes simultaneously in resting CD4+ T cells.
The advancements presented in this case study further illuminate the potential of genome editing in hard-to-transfect primary cells to drive research in human immunology and viral infection mechanisms.
Based on Albanese et al., Nature Methods 19, 81-89 (2022)
By implementing an optimized workflow that includes interleukin supplementation, sgRNA, and the 4D-Nucleofector® System, Dr. Manuel Albanese and his colleagues achieved knock out rates greater than 98% of up to six genes simultaneously in resting CD4+ T cells.
The advancements presented in this case study further illuminate the potential of genome editing in hard-to-transfect primary cells to drive research in human immunology and viral infection mechanisms.
Based on Albanese et al., Nature Methods 19, 81-89 (2022)
